Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells
DN Amin, DR Bielenberg, E Lifshits, JV Heymach… - Microvascular …, 2008 - Elsevier
Epidermal growth factor receptor (EGFR) targeting agents such as kinase inhibitors reduce
tumor growth and progression. We have previously reported that EGFR is not only
expressed by the tumor cells but by the tumor endothelial cells (EC) as well (Amin, DN, Hida,
K., Bielenberg, DR, Klagsbrun, M., 2006. Tumor endothelial cells express epidermal growth
factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase
inhibitors. Cancer Res. 66, 2173–80). Thus, targeting tumor blood vessel EGFR may be a …
tumor growth and progression. We have previously reported that EGFR is not only
expressed by the tumor cells but by the tumor endothelial cells (EC) as well (Amin, DN, Hida,
K., Bielenberg, DR, Klagsbrun, M., 2006. Tumor endothelial cells express epidermal growth
factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase
inhibitors. Cancer Res. 66, 2173–80). Thus, targeting tumor blood vessel EGFR may be a …